GIP and type 2 diabetes mellitus: The unique signaling mechanism of DPP-IV inhibitors, which involves delaying the degradation of incretin hormones (GLP-1 and GIP), causing decrease in glucagon release, and improving insulin secretion, has demonstrated a significant impact on the treatment of type 2 diabetes [56].